Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2021 May 17.

Published in final edited form as: Cancer Chemother Pharmacol. 2019 May 17;84(2):359–371. doi: 10.1007/s00280-019-03863-w

Fig. 5 — a Concentration response curves in three representative NCI60 panel cell lines after compound exposure for 2 days (blue), 3 days (red), 7 days (yellow) or 11 days (green) for the PARP inhibitors rucaparib, niraparib, olaparib, talazoparib, and veliparib. b Concentration response curves in three representative NCI60 panel cell lines after compound exposure for 2 days (blue), 3 days (red), 7 days (yellow) or 11 days (green) for the SMO inhibitors saridegib and LEQ-506 and the IAP inhibitors birinapant and LCL-161

Fig. 5 — a Concentration response curves in three representative NCI60 panel cell lines after compound exposure for 2 days (blue), 3 days (red), 7 days (yellow) or 11 days (green) for the PARP inhibitors rucaparib, niraparib, olaparib, talazoparib, and veliparib. b Concentration response curves in three representative NCI60 panel cell lines after compound exposure for 2 days (blue), 3 days (red), 7 days (yellow) or 11 days (green) for the SMO inhibitors saridegib and LEQ-506 and the IAP inhibitors birinapant and LCL-161